A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer

Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D. A., Rakiec, D. P., Korn, J. M., McAllister, G., Stegmeier, F. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 56

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma

Hartog, H., Horlings, H. M., van der Vegt, B., Kreike, B., Ajouaou, A., van de Vijver, M. J., Boezen, H. M., de Bock, G. H., van der Graaf, W. T. A., & Wesseling, J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1256-6 · Cited by 56

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

Zhu, Y., Zhang, X., Liu, Y., Zhang, S., Liu, J., Ma, Y., & Zhang, J. (2012) · Tumor Biology · doi:10.1007/s13277-012-0383-6 · Cited by 55

Acquisition of chromosome instability is a mechanism to evade oncogene addiction

Salgueiro, L., Buccitelli, C., Rowald, K., Somogyi, K., Kandala, S., Korbel, J. O., & Sotillo, R. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910941 · Cited by 58

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance

Russo, R. I. C., Béguelin, W., Flaqué, M. C. D., Proietti, C. J., Venturutti, L., Galigniana, N. M., Tkach, M., Guzmán, P., Roa, J. C., O’Brien, N. A., et al. (2014) · Oncogene · doi:10.1038/onc.2014.272 · Cited by 54

New phosphatidylinositol 3-kinase inhibitors for cancer

Bowles, D. W., & Jimeno, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562192 · Cited by 54

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives

Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 55

Resistance to human epidermal growth factor receptor type 2-targeted therapies

Théry, J., Spano, J., Azria, D., Raymond, É., & Penault-Llorca, F. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.003 · Cited by 54

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Scaltriti, M., Serra, V., Normant, E., Guzmán, M., Rodríguez, O., Lim, A. R., Slocum, K. L., West, K. A., Rodriguez, V., Prudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0966 · Cited by 54

Biomarkers of drugs targeting HER ‐family signalling in cancer

Montemurro, F., & Scaltriti, M. (2013) · The Journal of Pathology · doi:10.1002/path.4269 · Cited by 56

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression

Mukohara, T., Shimada, H., Ogasawara, N., Wanikawa, R., Shimomura, M., Nakatsura, T., Ishii, G., Park, J. O., Janne, P. A., Saijo, N., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.056 · Cited by 54

Cancer cell intrinsic TIM-3 induces glioblastoma progression

Guo, Q., Shen, S., Guan, G., Zhu, C. Y., Zou, C., Cao, J., Cheng, W., Xu, X., Yu, J., Lin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105329 · Cited by 55

Basal/HER2 breast carcinomas

Martín-Castillo, B., Oliveras‐Ferraros, C., Vázquez‐Martín, A., Cufí, S., Moreno, J. M., Corominas-Faja, B., Urruticoechea, A., Martín, Á. G., López‐Bonet, E., & Menéndez, J. A. (2013) · Cell Cycle · doi:10.4161/cc.23274 · Cited by 52

Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)

Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 53

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

Raja, S. M., Luan, H., Naramura, M., Bailey, T., Clubb, R. J., Band, V., & Band, H. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.90442 · Cited by 53

Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines

Gu, L., Lau, S. K., Loera, S., Somlo, G., & Kane, S. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0585 · Cited by 53

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Wang, S., Huang, J., Lyu, H., Cai, B., Yang, X., Li, F., Tan, M. J., Edgerton, S. M., Thor, A. D., Lee, C., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3563 · Cited by 53

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

An, E., Ock, C., Kim, T.-Y., Lee, K. H., Han, S., Im, S., Kim, T.-Y., Liao, W., Cecchi, F., Blackler, A. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw442 · Cited by 53

The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor

Sarwar, M., Khaja, A. S. S., Aleskandarany, M. A., Karlsson, R. T. G., Althobiti, M. M., Ødum, N., Mongan, N. P., Dizeyi, N., Johnson, H., Green, A. R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0438-2 · Cited by 53

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

Shah, M. A., Kang, Y., Thuss-Patience, P. C., Ohtsu, A., Ajani, J. A., Cutsem, E. V., Hoersch, S., Harle-Yge, M.-L., & de Haas, S. L. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00923-7 · Cited by 53

HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer

Sampera, A., Sánchez-Martín, F. J., Arpí, O., Visa, L., Iglesias, M., Menéndez, S., Gaye, É., Dalmases, A., Clavé, S., Gelabert‐Baldrich, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0455 · Cited by 56

Resistance to Anti-HER2 Therapies in Breast Cancer

Rimawi, M. F., Angelis, C. D., & Schiff, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e157 · Cited by 52

Elevated PI3K signaling drives multiple Breast Cancer subtypes

Adams, J. R., Schachter, N. F., Liu, J. C., Zacksenhaus, E., & Egan, S. E. (2011) · Oncotarget · doi:10.18632/oncotarget.285 · Cited by 51

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

Astanehe, A., Finkbeiner, M., Krzywinski, M. I., Fotovati, A., Dhillon, J., Berquin, I. M., Mills, G. B., Marra, M. A., & Dunn, S. E. (2012) · Oncogene · doi:10.1038/onc.2011.617 · Cited by 52

Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors

Rottenberg, S., Vollebergh, M. A., de Hoon, B., de Ronde, J., Schouten, P. C., Kersbergen, A. J., Zander, S. A. L., Pajic, M., Jaspers, J. E., Jonkers, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4201 · Cited by 52

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Wisinski, K. B., Tevaarwerk, A. J., Burkard, M. E., Rampurwala, M. M., Eickhoff, J. C., Bell, M. C., Kolesar, J., Flynn, C. M., & Liu, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2365 · Cited by 52

Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications

Rexer, B. N., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0687 · Cited by 51

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer

Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J. L., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217112 · Cited by 54

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program

Schramm, A., Friedl, T. W. P., Schochter, F., Scholz, C., de Gregorio, N., Huober, J., Rack, B. K., Trapp, E. K., Alunni‐Fabbroni, M., Müller, V., et al. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3879-7 · Cited by 51

Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer

Kulkarni, S., Reddy, K. B., Esteva, F. J., Moore, H. C. F., Budd, G. T., & Tubbs, R. R. (2009) · Oncogene · doi:10.1038/onc.2009.422 · Cited by 55

Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer

Emde, A., Köstler, W. J., & Yarden, Y. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.09.002 · Cited by 52

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity

Bajpe, P. K., Prahallad, A., Horlings, H. M., Nagtegaal, I. D., Beijersbergen, R. L., & Bernards, R. (2014) · Oncogene · doi:10.1038/onc.2013.588 · Cited by 51

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

Lee, J., Bartholomeusz, C., Mansour, O. C., Humphries, J., Hortobágyi, G. N., Ordentlich, P., & Ueno, N. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3014-7 · Cited by 51

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

Wetterskog, D., Shiu, K.-K., Chong, I. Y.-S., Meijer, T. G., Mackay, A. G., Lambros, M. B. K., Cunningham, D., Reis-Filho, J. S., Lord, C. J., & Ashworth, A. (2013) · Oncogene · doi:10.1038/onc.2013.41 · Cited by 51

Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside

Rodon, J. A., Pérez-García, J. M., & Kurzrock, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0117 · Cited by 50

Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers

Song, C., Park, S. Y., Eom, K., Kim, J. H., Kim, S., Js, K., & Kim, I. A. (2010) · Breast Cancer Research · doi:10.1186/bcr2557 · Cited by 54

Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy

Faratian, D., Sims, A. H., Mullen, P., Kay, C., Um, I., Langdon, S. P., & Harrison, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023772 · Cited by 51

Systems Biology Approaches and Tools for Analysis of Interactomes and Multi-target Drugs

Schrattenholz, A. S., Groebe, K., & Šoškić, V. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-800-3_2 · Cited by 52

Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies

Singer, C. F., Köstler, W. J., & Hudelist, G. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.02.003 · Cited by 51

Novel inhibitors of the PI3K family

Carnero, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066798 · Cited by 53

The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer

Hayes, N. V. L., & Gullick, W. J. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9078-4 · Cited by 51

MicroRNAs in cancer therapeutic response: Friend and foe

Xue, J. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.730 · Cited by 50

Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease

Seeger‐Nukpezah, T., Proia, D. A., Egleston, B. L., Nikonova, A. S., Kent, T., Cai, K. Q., Hensley, H. H., Ying, W., Chimmanamada, D., Serebriiskii, I. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301904110 · Cited by 50

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

Tracey, N., Creedon, H., Kemp, A. J., Culley, J., Muir, M., Klinowska, T. C. M., & Brunton, V. G. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05489-1 · Cited by 50

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review

Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., & Wang, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413376 · Cited by 50

Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance

Gu, L., Waliany, S., & Kane, S. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006220 · Cited by 50

Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells

Matevossian, A., & Resh, M. D. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0345-x · Cited by 50

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

Gayle, S. S., Arnold, S. L. M., O'Regan, R. M., & Nahta, R. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799015002 · Cited by 50

Monoclonal Antibody against the Ectodomain of E-Cadherin (DECMA-1) Suppresses Breast Carcinogenesis: Involvement of the HER/PI3K/Akt/mTOR and IAP Pathways

Brouxhon, S. M., Kyrkanides, S., Teng, X., Raja, V., O’Banion, M. K., Clarke, R. C., Byers, S. W., Silberfeld, A., Tornos, C. S., & Ma, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2747 · Cited by 50

Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation

Daverey, A., Drain, A. P., & Kidambi, S. (2015) · Scientific Reports · doi:10.1038/srep13744 · Cited by 50

Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo

Han, X., Zhang, X., Li, H., Huang, S., Zhang, S., Wang, F., & Shi, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5334 · Cited by 49

The pharmacological point of view of resistance to therapy in tumors

Damia, G. L. M., & Garattini, S. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.008 · Cited by 48

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

Elster, N., Cremona, M., Morgan, C., Toomey, S., Carr, A., O’Grady, A., Hennessy, B. T., & Eustace, A. J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3239-5 · Cited by 49

Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma

Paulsson, J., Lindh, M. B., Jarvius, M., Puputti, M., Nistér, M., Nupponen, N. N., Paulus, W., Söderberg, O., Dresemann, G. P., von Deimling, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25528 · Cited by 49

Role of erbB3 receptors in cancer therapeutic resistance

Lee, Y., Ma, J., Lyu, H., Huang, J., Kim, A., & Liu, B. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt150 · Cited by 49

HER-2-positive metastatic breast cancer: trastuzumab and beyond

Metro, G., Mottolese, M., & Fabi, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2583 · Cited by 49

Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling

Riehle, R. D., Cornea, S., & Degterev, A. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-6331-9_7 · Cited by 49

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Loibl, S., Darb‐Esfahani, S., Huober, J., Klimowicz, A. C., Furlanetto, J., Lederer, B., Hartmann, A., Eidtmann, H., Pfitzner, B. M., Fasching, P. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0965 · Cited by 49

CDK4/6 inhibitors in HER2-positive breast cancer

Corona, S. P., Ravelli, A., Cretella, D., Cappelletti, M. R., Zanotti, L., Dester, M., Gobbi, A., Petronini, P. G., & Generali, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.022 · Cited by 50

Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway

Akhtar, S., Hourani, S., Therachiyil, L., Al‐Dhfyan, A., Agouni, A., Zeidan, A., Shahab Uddin, M. S., & Korashy, H. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.014 · Cited by 49

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Chen, Q., Ouyang, D., Anwar, M., Xie, N., Wang, S., Fan, P., Qian, L., Chen, G., Zhou, E., Guo, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00811 · Cited by 48

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

Ferrando‐Díez, A., Felip, E., Pous, A., Bergamino, M. A., & Vila, M. M. (2022) · Cancers · doi:10.3390/cancers14143305 · Cited by 48

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH

Kirkegaard, T., Witton, C. J., Edwards, J., Nielsen, K. V., Jensen, L., Campbell, F., Cooke, T. G., & Bartlett, J. M. S. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03467.x · Cited by 48

Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells

Chang, H.-Y., Huang, T.-C., Chen, N.-N., Huang, H.-C., & Juan, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.504 · Cited by 48

Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers

Boyer, A. P., Collier, T. S., Vidavsky, I., & Bose, R. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.020115 · Cited by 48

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer

Farrugia, M. K., Sharma, S. B., Lin, C.-C., McLaughlin, S. L., Vanderbilt, D. B., Ammer, A. G., Salkeni, M. A., Stoilov, P., Agazie, Y. M., Creighton, C. J., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.65 · Cited by 49

Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice

Wang, L., Xie, Y., Ahmed, K. A., Ahmed, S., Sami, A., Chibbar, R., Xu, Q., Kane, S. E., Hao, S., Mulligan, S. J., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2626-7 · Cited by 48

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

Rowe, D. L., Ozbay, T., Bender, L. M., & Nahta, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0012 · Cited by 48

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2 V659E Mutation

Serra, V., Vivancos, A. P., Puente, X. S., Felip, E., Silberschmidt, D., Caratù, G., Parra, J.-L., Mattos‐Arruda, L. D., Grueso, J., Hernández‐Losa, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0132 · Cited by 48

The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment

Qin, H., Liu, L., Sun, S., Zhang, D., Sheng, J., Li, B., & Yang, W. (2018) · PeerJ · doi:10.7717/peerj.5092 · Cited by 48

Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer

Ligorio, F., Pellegrini, I., Castagnoli, L., Vingiani, A., Lobefaro, R., Zattarin, E., Santamaria, M., Pupa, S. M., Pruneri, G., de Braud, F., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.023 · Cited by 49

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition

Zardavas, D., Fumagalli, D., & Loi, S. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328358a2b5 · Cited by 47

IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance

White, C. D., Li, Z., Dillon, D. A. R., & Sacks, D. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.220939 · Cited by 47

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

Park, Y. H., Jung, H. A., Choi, M. K., Chang, W., Choi, Y., Do, I.-G., Ahn, J. S., & Im, Y.-H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.757 · Cited by 47

Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer

Vu, T., Sliwkowski, M. X., & Claret, F. X. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.007 · Cited by 47

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance

Huang, X., Wang, S., Lee, C., Yang, X., & Liu, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.019 · Cited by 47

Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient

Hirotsu, Y., Nakagomi, H., Amemiya, K., Oyama, T., Inoue, M., Mochizuki, H., & Omata, M. (2016) · Medical Oncology · doi:10.1007/s12032-016-0857-2 · Cited by 47

Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment

Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48

Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells

Belkhiri, A., Dar, A. A., Peng, D., Razvi, M. H., Rinehart, C., Arteaga, C. L., & El-Rifai, W. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0121 · Cited by 47

mTOR inhibitors in the treatment of breast cancer.

Vinayak, S., & Carlson, R. W. (2013) · PubMed · Cited by 46

New therapeutic approaches in breast cancer

Davies, E. L., & Hiscox, S. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.10.012 · Cited by 46

PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing

Bai, X., Zhang, E., Ye, H., Nandakumar, V., Wang, Z., Chen, L., Tang, C., Li, J., Li, H., Zhang, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099306 · Cited by 46

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Blagden, S. P., Olmin, A., Josephs, D. H., Stavraka, C., Zivi, A., Pinato, D. J., Anthoney, A., Decordova, S., Swales, K. E., Riisnaes, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1315 · Cited by 46

Targeted therapies in breast cancer

Rojo, F., Albanell, J., Rovira, A., Corominas, J. M., & Manzarbeitia, F. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.08.001 · Cited by 44

Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression

Keune, W., Sims, A. H., Jones, D. R., Bultsma, Y., Lynch, J. T., Jirström, K., Landberg, G., & Divecha, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0424 · Cited by 46

A pan-HER approach for cancer therapy: background, current status and future development

Huang, Z., Brdlik, C. M., Jin, P., & Shepard, H. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802630427 · Cited by 45

HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBPβ Isoforms

Estape, A. A., Tarragona, M., Morales, M. L. G., Guiu, M., Nadal, C., Massagué, J., & Gomis, R. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0869 · Cited by 46

PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

Cheng, H.-L., Liu, P.-X., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W., Lin, N., Krop, I., Roberts, T., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 40

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 48

PI3K inhibition to overcome endocrine resistance in breast cancer

Keegan, N. M., Gleeson, J. P., Hennessy, B. T., & Morris, P. G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417384 · Cited by 48

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP

Takano, T., Tsurutani, J., Takahashi, M., Yamanaka, T., Sakai, K., Ito, Y., Fukuoka, J., Kimura, H., Kawabata, H., Tamura, K., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.04.010 · Cited by 46

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer

Schwill, M., Tamaskovic, R., Gajadhar, A. S., Kast, F., White, F. M., & Plückthun, A. (2019) · Science Signaling · doi:10.1126/scisignal.aau2875 · Cited by 46

A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation

Kalofonou, M., Malpartida-Cardenas, K., Alexandrou, G., Rodríguez-Manzano, J., Yu, L., Miscourides, N., Allsopp, R. C., Gleason, K. L. T., Goddard, K., Fernández-García, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60852-3 · Cited by 47

Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification

Negri, T., Tarantino, E., Orsenigo, M., Reid, J. F., Gariboldi, M., Zambetti, M., Pierotti, M. A., & Pilotti, S. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20798 · Cited by 45

The role of targeted therapy and biomarkers in breast cancer treatment

Stopeck, A., Brown-Glaberman, U. A., Wong, H. Y., Park, B. H., Barnato, S. E., Gradishar, W. J., Hudis, C. A., & Rugo, H. S. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9496-y · Cited by 46

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients

Xu, B.-H., Jiang, Z.-F., Chua, D. T. T., Shao, Z.-M., Luo, R.-C., Wang, X.-J., Liu, D.-G., Yeo, W., Yu, S., Newstat, B. O., et al. (2011) · 癌症：英文版 · doi:10.5732/cjc.010.10507 · Cited by 45

Partial PTEN deletion is linked to poor prognosis in breast cancer

Lebok, P., Kopperschmidt, V., Kluth, M., Hube‐Magg, C., Özden, C., Taskin, B., Hussein, K. R., Mittenzwei, A., Lebeau, A., Witzel, I., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1770-3 · Cited by 45

PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma

Deguchi, Y., Okabe, H., Oshima, N., Hisamori, S., Minamiguchi, S., Muto, M., & Sakai, Y. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0627-z · Cited by 45

Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer

Greville, G., McCann, A. H., Rudd, P. M., & Saldova, R. (2016) · Epigenetics · doi:10.1080/15592294.2016.1241932 · Cited by 43

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285

PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?

Park, B. H., & Davidson, N. E. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.004 · Cited by 47

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30

An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib.

Hu, X., Wang, L. P., Zhang, Q. L., Zhang, J., Guo, H., Sun, S., Wang, B. Y., Jia, Z., Shao, Z. M., & Wang, Z. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.541

Abstract P3-07-11: High activation of PI3K pathway defined by PIK3CA mutation, PTEN, and INPP4B expression are associated with trastuzumab efficacy in HER2-positive breast cancer

Sueta, A., Yamamoto, Y., Takeshita, T., Yamamoto‐Ibusuki, M., & Iwase, H. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p3-07-11